Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
- Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers
- Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20mg veledimex cohort who received Controlled IL-12 as a single agent
- Over expression of immune checkpoint biomarkers demonstrated
- Abscopal anti-tumor effect documented in metastatic breast cancer
- Data strongly support development of Controlled IL-12 platform in combination with immune checkpoint inhibitors
The poster, “Demonstration of Anti-Tumor Immunity via Intratumoral Regulated Platform Ad-RTS-hIL-12 in Advanced Breast Cancer and Recurrent Glioblastoma Patients,” presented data from two open-label trials that evaluated Ad-RTS-hIL-12 plus veledimex, a gene therapy designed to induce and control the expression of the powerful cytokine interleukin 12 (IL-12). The poster is available on the Company’s website.
Updated data from the Company’s Phase 1 rGBM study shows median overall survival (mOS) of 12.7 months has been sustained for patients treated with Ad-RTS-hIL-12 plus 20mg of veledimex (n=15) at a mean follow-up time of 12.9 months as of
“We remain excited that Ad-RTS-hIL-12 plus veledimex as monotherapy demonstrates promising antitumor responses and makes cold tumors hot with new immune infiltrating cells and overexpression of checkpoints,” said
In both rGBM and mBC trials, an adenovirus vector with coding for the RheoSwitch Therapeutic System® (RTS®) genetic switch and IL-12 was injected intratumorally and patients took oral doses of veledimex, an activator ligand which controls IL-12 production at the tumor site. The protocol for rGBM trial allowed for patients to receive doses of veledimex between 10 and 40 mg daily over 14 days while patients with mBC received 80mg of veledimex daily for seven days.
In both tumor types, biopsy data showed consistent, dose-dependent production of IL-12 and interferon gamma and an influx of CD3+ CD8+ cytotoxic T cells. Additionally, there was evidence of sustained intratumoral increase in interferon gamma with undetectable levels of cytokines in systemic circulation in both studies. In the rGBM study, immunofluorescence studies show an overexpression of PD-1/PD-L1 markers.
In the mBC study, disease control rate was 44 percent at week 6 and 22 percent at week 12. Reductions in the diameter of both injected and non-injected lesions was observed and considered evidence of an abscopal effect.
Overall, Ad-RTS-hIL-12 plus veledimex revealed a consistent and attractive safety profile. In both studies, low grade dose-related transient cytokine release syndrome was the most commonly observed adverse reaction. Drug related toxicities were predictable, dose-related, and fully reversible upon discontinuation of veledimex.
About Controlled IL-12
Ad-RTS-hIL-12 plus veledimex is a novel gene therapy candidate designed to express human interleukin-12 (hIL-12) under the control of an orally administered activator ligand, veledimex, through a proprietary RheoSwitch Therapeutic System® (RTS®) gene switch. IL-12 is a powerful cytokine that has demonstrated a targeted, anti-tumor immune response with the ability to activate and recruit killer T cells to the tumor site. An ongoing Phase 1 trial is evaluating Ad-RTS-hIL-12 plus veledimex as a monotherapy to treat patients with rGBM, and a separate trial has been initiated to evaluate a single dose of Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint inhibitor targeting programmed death receptor-1 (PD-1). The Company also is enrolling pediatric patients in its Phase 1 trial of Ad-RTS-hIL-12 with veledimex for the treatment of brain tumors at multiple U.S. sites. The Company also is exploring combination therapies with Controlled IL-12 and checkpoint inhibitors in additional tumor types.
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's business and strategic plans as well as the progress and timing of the development of the Company's research and development programs, including the timing for the initiation of its clinical trials. All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: changes in the Company's financial condition and cash needs, funding or other strategic opportunities that become available to the Company, the Company's ability to finance its operations and business initiatives and obtain funding for such activities; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of other product candidates will advance further in the preclinical research or clinical trial process and whether and when, if at all, they will receive final approval from the
Source: ZIOPHARM Oncology Inc